Latest Cancer Research Stories
TSX Venture: QPT EDMONTON, Jan. 22, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has achieved 50% accrual having enrolled the 40(th) patient in its ongoing 80 patient Phase II Oregovomab front-line chemo-immunotherapy clinical trial in Italy and the U.S. The objective of this study is to confirm that optimally dosed oregovomab in...
CHOP researcher leads large multicenter gene sequencing study of neuroblastoma An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutations—mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to...
-- CHOP Researcher Leads Large, Multicenter Gene Sequencing Study of Neuroblastoma-- PHILADELPHIA, Jan. 20, 2013 /PRNewswire-USNewswire/ -- An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutations--mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now...
Krishagni, developer of caTissue Plus - an Enterprise edition of NCI caTissue, will integrate caTissue Plus with Aperio imaging system and OmniLab pathology system for UNSW, and provide ongoing support for the next three years. caTissue, developed by National Cancer Institute (NCI), is a free and open source Biobanking LIMS software. (PRWEB) January 17, 2013 Krishagni Solutions today announces collaboration with Translational Cancer Research Network (TCRN) of the University of New South...
ST. JOHN'S, NL, Jan. 17, 2013 /CNW/ - Dr. Ken Kao and his team at Memorial University of Newfoundland have made an important discovery that could lead to better detection and treatment methods for those diagnosed with prostate cancer. The two-year research project is funded in part through the Research & Development Corporation of Newfoundland and Labrador (RDC), a provincial Crown corporation. "Our province continues to be a place where life science researchers like Dr. Kao...
LAGUNA HILLS, Calif., Jan. 16, 2013 /PRNewswire/ -- NanoSmart Pharmaceuticals, a private biotechnology company, has entered into a research collaboration agreement with University of California Los Angeles (UCLA) to continue the development of NanoSmart's novel drug delivery platform for the treatment of cancer and other life-threatening diseases. "We are very excited to work closely with Dr. Noah Federman and his colleagues at UCLA, as they will provide access to an extraordinary...
The CBCD agrees with DNA Pioneer Dr. Watson. More risks need to be taken in cancer research. Rochester, NY (PRWEB) January 14, 2013 The Center for the Biology of Chronic Disease (CBCD) has learned that DNA pioneer and Nobel Prize winner, James Watson recently published a scathing article against America’s cancer research establishment. His paper was published in the journal, Open Biology and in it, he argued that the $100 million U.S. project to determine the DNA changes that drive nine...
US Storage Centers’ customers who participated in Kure It Cancer Research’s program ‘Round Up For Research’ raised $51,772 in 2012. This is a significant increase from the $38,117 raised in 2011. Newport Beach, CA (PRWEB) January 11, 2013 US Storage Centers’ customers who participated in Kure It Cancer Research’s program ‘Round Up For Research’ raised $51,772 in 2012. This is a significant increase from the $38,117 raised in 2011. Kure It is a registered 501(c)(3) and was...
One of the greatest challenges faced by cancer surgeons is to know exactly which tissue to remove, or not, while the patient is under anesthesia. A team of surgeons and scientists at University of California, San Diego School of Medicine have developed a new technique that will allow surgeons to identify during surgery which lymph nodes are cancerous so that healthy tissue can be saved. The findings will be published in the January 15 print edition of Cancer Research. "This research is...
By harnessing the very qualities that make sickle cell disease a lethal blood disorder, a research team led by Duke Medicine and Jenomic, a private cancer research company in Carmel, Calif., has developed a way to deploy the misshapen red blood cells to fight cancer tumors. Reporting in the Jan. 9, 2013, edition of the on-line journal, PLOS ONE, the researchers describe a process of exploiting sickle-shaped red blood cells to selectively target oxygen deprived cancer tumors in mice and...
